Lisa Richardson named director of CDC Division of Cancer Prevention and Control

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

LISA RICHARDSON was named director of the CDC Division of Cancer Prevention and Control.

Richardson served for over a decade in medical and scientific leadership roles in the division and will rejoin the center Nov. 16.

She first joined CDC in 1997 as medical officer in DCPC’s National Breast and Cervical Cancer Early Detection Program and was then selected as medical officer of the Hematologic Diseases Branch in the National Center for Infectious Diseases.

She left CDC in late 2000 to practice clinical care and serve as assistant professor at the University of Florida’s School of Medicine. Richardson then returned to CDC in 2004 as medical officer and served as lead of the Scientific Support and Clinical Translation Team in the Comprehensive Cancer Control Branch and as the division’s associate director for science. She then left DCPC in April 2013 to direct the Division of Blood Disorders in the National Center for Birth Defects and Developmental Disabilities.

Pamela Protzel Berman, who served as acting director of DCPC, will return to her full-time duties as DCPC’s deputy director.

Table of Contents

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login